接受脑转移放射治疗患者30天死亡率相关的临床因素
单中心回顾性纳入2017年1月1日至2020年9月30日接受立体定向放射外科或全脑放疗的636例脑转移患者,75例(11.7%)在放疗完成后30天内死亡。多因素分析显示进展性胸腔内病变、进展性肝和/或肾上腺转移及住院状态与30天死亡相关,较高KPS、初诊时同步脑转移及门诊姑息治疗使用与30天后生存相关。
要点
- 636例脑转移患者中75例(11.7%)在放疗完成后30天内死亡。
- 进展性胸腔内病变、进展性肝和/或肾上腺转移及住院状态与30天死亡相关。
- 较高KPS、初诊时同步脑转移及门诊姑息治疗使用与30天后生存相关。
核心结论
- 较低KPS、进展性胸腔内病变、进展性肝和/或肾上腺转移及住院状态与放疗后30天死亡相关。
- 较高KPS、初诊时脑转移及门诊姑息治疗使用与放疗后30天以上生存相关。
- 这些数据可能有助于识别哪些患者可能从脑转移定向放疗中获益。
研究设计与样本
- 单中心纳入2017年1月1日至2020年9月30日接受立体定向放射外科或全脑放疗的脑转移患者。
- 共636例患者,其中全脑放疗117例、立体定向放射外科519例。
- 采用Kaplan-Meier法估计中位总生存,采用单因素和多因素logistic回归评估30天死亡的相关因素。
主要发现
- 最常见原发疾病类型为非小细胞肺癌(46.7%)和乳腺癌(19.8%)。
- 中位生存时间为6个月(95%CI,5-7个月)。
- 636例患者中75例(11.7%)在放疗完成后30天内死亡。
- 多因素分析:进展性胸腔内病变HR 4.67(95%CI,2.06-10.60;P=.002),进展性肝和/或肾上腺转移HR 2.20(95%CI,1.16-3.68;P=.02),住院状态HR 4.51(95%CI,1.78-11.42;P=.002)。
- 多因素分析:较高KPS评分HR 0.95(95%CI,0.93-0.97;P<.001),初诊时同步脑转移HR 0.45(95%CI,0.21-0.96;P=.04),门诊姑息治疗使用HR 0.45(95%CI,0.20-1.00;P=.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Existing brain metastasis prognostic models do not identify patients at risk of very poor survival after radiation therapy (RT). Identifying patient and disease risk factors for 30-day mortality (30-DM) after RT may help identify patients who would not benefit from RT. METHODS AND MATERIALS: All patients who received stereotactic radiosurgery (SRS) or whole-brain RT (WBRT) for brain metastases from January 1, 2017, to September 30, 2020, at a single tertiary care center were included. Variables regarding demographics, systemic and intracranial disease characteristics, symptoms, RT, palliative care, and death were recorded. Thirty-day mortality was defined as death within 30 days of RT completion. The Kaplan-Meier method was used to estimate median overall survival. Univariate and multivariable logistic regression models were used to assess associations between demographic, tumor, and treatment factors and 30-DM. RESULTS: A total of 636 patients with brain metastases were treated with either WBRT (n = 117) or SRS (n = 519). The most common primary disease types were non-small cell lung (46.7%) and breast (19.8%) cancer. Median survival time was 6 months (95% CI, 5-7 months). Of the 636 patients, 75 (11.7%) died within 30 days of RT. On multivariable analysis, progressive intrathoracic disease (hazard ratio [HR], 4.67; 95% CI, 2.06-10.60; P = .002), progressive liver and/or adrenal metastases (HR, 2.20; 95% CI, 1.16-3.68; P = .02), and inpatient status (HR, 4.51; 95% CI, 1.78-11.42; P = .002) were associated with dying within 30 days of RT. A higher Karnofsky Performance Status (KPS) score (HR, 0.95; 95% CI, 0.93-0.97; P < .001), synchronous brain metastases at time of initial diagnosis (HR, 0.45; 95% CI, 0.21-0.96; P = .04), and outpatient palliative care utilization (HR, 0.45; 95% CI, 0.20-1.00; P = .05) were associated with surviving more than 30 days after RT. CONCLUSIONS: Multiple factors including a lower KPS, progressive intrathoracic disease, progressive liver and/or adrenal metastases, and inpatient status were associated with 30-DM after RT. A higher KPS, brain metastases at initial diagnosis, and outpatient palliative care utilization were associated with survival beyond 30 days. These data may aid in identifying which patients may benefit from brain metastasis-directed RT.
引用
- Natesan D, Carpenter DJ, Giles W, et al. Clinical Factors Associated With 30-Day Mortality Among Patients Undergoing Radiation Therapy for Brain Metastases. Adv Radiat Oncol. 2023. PMID: 37152484. doi:10.1016/j.adro.2023.101211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。